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Abstract
Over nearly half a century, transplantation methods have been
employed to regenerate the mammary gland in vivo. Recent highly
cited reports claim to have demonstrated the regeneration of an
entire functional mammary gland from a single mammary epithelial
cell. Nevertheless, re-examination of the literature on the
transplantation biology of mammary gland regeneration reveals that
a complex, combinatorial interaction between variously differen-
tiated mammary epithelial cells and the mammary fat pad stroma is
indispensable to this process. In the present article, these issues
are reviewed and discussed to provide a greater understanding of
the complexity of these multiplex interactions.
Early history
The experiments that demonstrate the presence of stem cells
in the mammary gland are based on the pioneering studies of
DeOme and his students, Les Faulkin and Charles Daniel.
The approach they used was serial transplantation of normal
mammary gland into the cleared mammary fat pad of
syngeneic mice [1,2]. The cleared fat pad transplantation
technique allowed the transplantation and growth of normal
mammary cells into their normal anatomical site and under the
influence of a normal physiological environment. Using this
method, they demonstrated that the normal mammary gland
contains cells that will grow and fill the fat pad with a normal
ductal mammary tree and will respond to hormones with a
normal differentiation program [3]. The progeny of the trans-
planted cells could be serially transplanted into the appro-
priate recipients multiple times; however, unlike preneoplastic
cells or neoplastic cells, the normal cells always senesced
after multiple serial transplants, generally five to eight trans-
plant generations [4]. This was interpreted as indicating that
the proliferative activity was a finite property of the stem cells.
This finite lifespan was a fundamental difference between
normal and preneoplastic/neoplastic mammary cells.
Subsequent studies demonstrated that stem cells were
located along the entire mammary tree and were represented
in the different developmental states of the mammary gland.
These stages included primary and tertiary ducts from 6-week
and 16-week virgin gland, uniparous and multiparous
regressed glands, and 15-day pregnant and 10-day lactating
glands [5]. Host age and reproductive history had little
influence on the frequency of stem cells as measured by the
percentage of successful takes and a lifespan assay [5,6].
Mammary cells from 26-month-old virgin mice had the same
transplant potential as cells taken from 3-week-old mice. Both
cell populations senesced after five transplant generations.
Similarly, continuous hormone stimulation did not induce
additional loss of ductal growth potential. These studies
suggested that the mammary stem cell is a relatively
quiescent cell that is only activated under conditions of gland
repopulation (that is, fetal growth stage, pubertal growth
phase). Under other conditions, such as pregnancy, it is
probable that ductal and alveolar progenitor cells form the
bulk of the increased mammary epithelial cell population [7].
These early studies demonstrated that the lifespan was
intricately linked to proliferation activity. For example, the
lifespan was correlated with the interval of serial
transplantation. Transplanting at 12-month intervals instead of
at 3-month intervals therefore prolonged the ultimate lifespan
of normal cells [8,9]. Similarly, transplanting from the
periphery of the ductal outgrowth (that is, such cells would
have undergone more cell divisions) resulted in earlier
senescence than transplanting cells from the center (that is,
the original transplant site) of the outgrowth. In summary,
these early studies suggested the presence of a mammary
cell that could repopulate the mammary gland and could
undergo a normal and complete morphogenic program (that
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is, a stem cell). Such cells were spaced throughout the
mammary tree, were quiescent and had a finite lifespan.
A commonly stated assumption that normal mammary stem
cells are an ideal target for oncogenic transformation
because they, like cancer cells, share a long lifespan (that is,
replicative potential) is not supported by the transplantation
results. At least for the mammary gland, the evidence to date
suggests that mammary stem cells have a finite lifespan.
Although untested, another possibility for the appearance of
growth senescence might be due to failure of the micro-
environment (niche) to provide the signals appropriate for
stem cell self-renewal. This deficiency would, by necessity,
involve the epithelial cell population surrounding the stem cell
proper since transplantation always occurs into young
mammary fat pad stroma. A corollary to this possibility would
be that signals emanating from the transformed progeny
surrounding the self-renewing premalignant/tumorigenic cell
rather than a property intrinsic to the premalignant/
tumorigenic cell are responsible for the infinite replicative
lifetime of an immortalized mammary population.
Lineage-limited progenitors among mammary
epithelium
Evidence for lobule-limited and duct-limited pluripotent
mammary epithelial cell activities has been established for
both rats and mice by transplantation of limiting dilutions of
dispersed mammary epithelial cells into hosts that were sub-
sequently impregnated and/or treated with hormone combi-
nations to produce alveologenesis [7,10-13]. These limited
structures contain both luminal epithelial cells and luminal
myoepithelial cells. Studies with retrovirally marked clonal
mammary populations demonstrated that both of these
lineage-limited activities were present within the clonal
populations through repeated transplant generations, indica-
ting their derivation from a single pluripotent antecedent
[10,13]. In addition, serial passage of the retrovirally marked
mammary epithelial clones in pregnant hosts showed that the
capacity of individual outgrowths to produce lobulogenesis or
ductal elongation were independently lost during the
acquisition of growth senescence among individual
transplants [13].
The distinction between these two progenitor-mediated
activities in regenerating mammary tissue is that the lobule-
limited progenitor is unable to produce cap cells, which are
required for the penetration of the mammary fat pad at the
tips of the growing terminal end buds. On the other hand,
duct-limited progenitors fail to produce progeny capable of
sustaining alveolar development and growth during
pregnancy. With the development of the WAP-Cre model
used in combination with the Rosa26LacZ reporter mice,
evidence surfaced for a LacZ-marked lobular-limited progenitor
observable in parous mouse mammary epithelium [14]. These
LacZ-positive, parity-identified mammary cells (PI-MEC) were
found to be pluripotent, self-renewing and capable of
maintaining their lobule-limited progenitor activities following
serial transplantation in epithelium-free mammary fat pads
when the hosts were subsequently impregnated [15]. During
pregnancy in these hosts, the PI-MEC proliferated and gave
rise to LacZ-positive luminal progeny that were progesterone
receptor (PR)-positive or estrogen receptor alpha (ERα)-
positive and to luminal progeny that were bereft of these
steroid receptors. Further in the developing secretory acini,
they contributed not only secretory progeny but also LacZ-
positive myoepithelial cells.
Originally it was proposed that the LacZ-positive PI-MEC
arose from de-differentiated secretory epithelial cells that had
survived involution and remodeling of the mammary tissue;
however, further study indicated that these cells were present
in the mammary tissue of nulliparous females and that they
could be detected in explant cultures after treatment of the
fragments with growth factors that do not induce lactogenic
differentiation [16]. These cells were shown to possess all
the properties of PI-MEC, including self-renewal and pluri-
potency. These observations support and confirm those
reported earlier [7], which indicated the presence of lobule-
limited progenitor activity in limiting dilution transplants of epi-
thelium from nulliparous donors in pregnant transplant hosts.
More recent evidence demonstrates that PI-MEC are marked
by the expression of green fluorescent protein (GFP) in WAP-
Cre/chicken actin gene promoter flox–stop–flox–GFP parous
females. In these studies, GFP+ PI-MEC were fluorescent
activated cell sorted and found to be virtually 100% present
in the CD49fhi population [17]. This population was shown
earlier to possess essentially all of the mammary repopulating
activity [18]. Subsequent transplantation of GFP+/CD49fhi-
positive PI-MEC and the GFP–/CD49flo epithelial cells into
epithelium-divested mammary fat pads indicated that all of
the repopulating activity was associated with the GFP+
fraction [17].
The foregoing data and the observations reported earlier [15]
suggest strongly that PI-MEC (that is, lobule-limited progeni-
tors) are indispensable to mammary gland ductal reconsti-
tution in transplanted mammary fat pads.
With respect to tumorigenesis, both lobule-limited hyper-
plasia and duct-limited hyperplasia have been repeatedly
isolated and propagated from mouse mammary glands
[19,20]. These populations do not exhibit growth senescence
upon serial passage, and most exhibit an increased
predilection for developing stochastic mammary tumors. Their
existence strongly implicates the lobule-limited and duct-
limited mammary stem/progenitor cells as targets for
tumorigenic transformation. These premalignant lesions have
been variously induced in the mammary epithelium by
hormonal treatment, mouse mammary tumor virus (MMTV),
chemical carcinogens and combinations of these agents
[19-21]. The MMTV-infected populations have beenPage 3 of 6
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definitively demonstrated to be clonally derived, indicating
that the hyperplasia and the subsequent mammary tumors
have arisen from a single transformed cell [22]. Likewise,
transplantation of nontransformed, normal MMTV-infected
mammary tissue fragments give rise to clonal populations,
indicating that all cells in the fragment capable of contributing
progeny to the glandular outgrowth have derived from the
same MMTV-infected antecedent. As mentioned earlier, the
normal clones contain both lobule-limited progenitor/stem
cells and duct-limited progenitor/stem cells and they exhibit
growth senescence upon serial passage [10,13].
Dispersed cell implantation compared with
fragment: clonal or combinatorial
It has been shown – both directly by retroviral tagging in
serially transplanted MMTV-infected mammary outgrowths
and, more recently, by implantation of visually confirmed
single cells – that an entire functional mammary gland may be
developed from the progeny of a single cell. On the contrary,
considerable evidence exists that transplantation of
dispersed mammary epithelial cells comprised of unsorted
heterogeneously marked epithelial cells produce complete
outgrowths that are frequently (in some cases, invariably)
mixtures of the progeny derived from the variously marked
donor cells [14,15,17,23,24].
In the absence of ERα expression, duct elongation and
development fails in both pubertal females and parous
females [23]. The amphiregulin null mouse mammary gland
phenocopies this deficiency, indicating that amphiregulin is a
major duct-specific growth signal mediated through ERα-
positive mammary epithelial cells. Despite this indication, both
ERαnull mammary epithelial cells and amphiregulin null
mammary epithelial cells are capable of contributing progeny
to all mammary epithelial subtypes when dispersed and mixed
with wild-type mammary epithelium before injection into
cleared mammary fat pads [23,24]. The evidence from PR
null models reveals that alveologenesis cannot proceed in the
absence of paracrine signals from PR-positive epithelial cells
[25]. Nevertheless, dispersed PRnull cells marked by LacZ
expression contribute alveolar progeny when mixed with wild-
type epithelial cells in pregnant hosts. This observation clearly
demonstrates that a complete mammary epithelial outgrowth
cannot be formed without ERα-positive and PR-positive
epithelial cell subtypes. These findings argue that a single
mammary cell injected into an empty mammary fat pad must,
at a minimum, divide asymmetrically (and remain a stem/
progenitor cell) to produce an ERα-positive daughter and
later again to produce cap cell progeny in order to begin
ductal growth, and still later to produce a PR-positive cell to
support side branching and subsequently alveologenesis.
The clear existence of lineage-limited, pluripotent duct and
lobule progenitors within the nulliparous mouse mammary
epithelium raises the strong probability that these cells might
combine to produce mammary outgrowths comprising both
ductal and lobular development when inoculated in dispersed
cell populations. PI-MEC (that is, lobule-limited stem/
progenitor cells) produce PR-positive and ERα-positive
progeny as well as progeny negative for these receptors
when contributing to mammary outgrowths in the pregnant
host [15]. Similar findings were obtained when duct-limited
outgrowths were tested for the presence of these steroid
nuclear receptors. These results indicate that each of these
lineage-limited stem/progenitors is capable of producing cell
progeny shown above to be indispensable for complete
mammary development. The lines between the primary
antecedent and the downstream stem/progenitors therefore
become blurred regarding their relative importance in
producing complete mammary outgrowths in transplanted fat
pads. Serial transplantation of clonal populations by fragment
implantation into subsequently impregnated hosts showed
that the capacity of any given fragment to produce
alveologenesis and/or duct elongation was lost independently
during the onset of growth senescence [13]. Serially
transplanted growth senescent duct fragments were earlier
shown to be able to generate lobuloalveolar growth upon
impregnation of the transplant host [9]. The conclusion drawn
from these observations postulates that either each lineage-
limited stem/progenitor activity decays independently from
the other during outgrowth development or that the primary
mammary stem cell loses the capacity to produce one or the
other lineage-limited downstream stem/progenitor during its
own self-renewal while expanding in the previous generation.
To summarize, both dispersed cell and fragment implantation
led to mammary epithelial outgrowths comprised of progeny
produced by independently self-renewing stem/progenitor
populations. These facts do not in any way dispute the
existence of a primary mammary stem cell antecedent. They
do indicate, however, the persistence of multiple pluripotent
stem/progenitor cell activities within the mammary epithelial
population that are capable of independently contributing
diverse epithelial progeny during mammary gland growth and
regeneration.
What is relevance of immortal lineage-limited
transplantable populations to the cancer
stem cell debate?
A massive scientific literature exists that identifies and
characterizes the presence of premalignant mammary
epithelial lesions in rodents. These lesions are transplantable
to epithelium-divested mammary fat pads, as in normal
mammary epithelium, and grow maintaining their hyperplastic
phenotype [19,20]. Unlike normal mammary outgrowths,
these populations do not exhibit growth senescence upon
serial transplantation. Similar to normal mammary outgrowths,
they fail to grow in ectopic sites, do not overgrow normal
mammary outgrowths within the same fat pad and cease to
grow when the confines of the mammary fat pad are reached.
These populations exhibit a greater tendency to develop focal
mammary tumors than normal mammary outgrowths.
Available online http://breast-cancer-research.com/content/10/1/203Two major phenotypic premalignant immortal populations
have been isolated, those populations that maintain a
lobular–alveolar morphology and growth pattern in the
absence of pregnancy and those that grow with a ductal
morphology. It is tempting to ascribe the origins of these
premalignant populations to immortalized lobule-limited
progenitors and duct-limited progenitors, respectively, which
would mean these lineage-limited progenitors are targets for
malignant transformation. Both of these populations comprise
luminal and myoepithelial cell types in keeping with the
pluripotent nature of the lineage-limited progenitors. Many of
the ductal hyperplasia lines (that is, EL-12) can be induced
with hormonal stimulation to form secretory alveoli. Others
(that is, EL-11) are refractory to alveolar development upon
hormonal treatment or even in full-term pregnant hosts [26,27].
These latter populations in all probability contain only duct-
limited stem/progenitors. Alveolar hyperplastic outgrowths
are unable to produce terminal end buds with their charac-
teristic cap cells and are therefore unable to produce ducts;
instead they expand radially in a manner that is presently
poorly understood. The hypothesis is that these populations
are supported entirely by transformed lobule-limited
stem/progenitors. This has not yet been definitively proven.
The  in situ lesions, hyperplastic alveolar nodules and hyper-
plastic ductal lesions that give rise to the immortalized
outgrowths described above may be considered analogous to
early-stage hyperplastic lesions described in the human breast
(for example, hyperplastic enlarged lobular units and proliferative
disease without atypia), and as such may reveal important clues
to the etiology of these human breast lesions upon further study.
We suggest these models indicate that self-renewing
pluripotent mammary cells other than the primordial mammary
stem cell can be targets for neoplastic transformation.
What are long label-retaining cells: unique to
stem cells or mixed?
Long DNA label retention has repeatedly been ascribed as a
property of stem cells due to their supposed absence of
mitotic activity during tissue homeostasis. Recent studies
have indicated that long label-retaining cells in a variety of
tissues actually cycle and retain their original labeled DNA
template strands. This has been demonstrated in the intact
mouse mammary gland and in outgrowths from transplants of
mammary epithelium into cleared mammary fat pads [28]. In
both instances, label-retaining epithelial cells following pro-
longed chase periods were labeled by a second DNA
analogue and were shown to transmit the second label
(associated with newly synthesized DNA strands) to their
immediate progeny. This property was demonstrated for ERα-
positive, PR-positive mammary epithelium as well as those
not expressing these receptors [29]. In addition, lobule-
limited alveolar stem/progenitors (PI-MEC) were shown by
Smith to adopt this method of asymmetric division (that is,
selective template DNA segregation) in growing transplants
in nonpregnant hosts [28].
These observations indicate that the property of selective
segregation of DNA strands by asymmetrically dividing cells
is not only a property of stem cells but also of lineage-limited
stem/progenitors, and perhaps specific transit amplifying
committed epithelial cells as well. Much more study of this
important asymmetric mitotic event is required and necessary
to establish both the mechanism for this selective
segregation and to understand its role in tissue development,
differentiation, repair and maintenance.
Immortality versus senescence: role of stem
cells versus niche
One of the primary findings made through transplantation of
mammary tissue into the cleared mammary fat pads was the
recognition that growth senescence was reached during
serial transplantation of normal mammary epithelium but was
not observed when premalignant mammary tissue was
proliferated in the same way [1]. This paradox remains a
mystery. This property of proliferative immortality is a property
of premalignant mammary epithelium irrespective of the
initiating treatment, whether it is viral, hormonal or chemical.
Proliferatively immortal lines were also selected from
mammary epithelial cells propagated in vitro. It was shown in
selected lines that immortality during transplantation and the
increased propensity to develop focal neoplastic lesions were
unlinked [26]. Some of these lines showed no trend to
develop focal mammary tumors.
The immortality phenotype may be considered linked to self-
renewal, as molecular markers (such as retroviral insertions)
specific for any specific immortalized premalignant mammary
population are stable and reproducible through successive
generations. It is commonly held that growth senescence
during serial transplantation of normal gland results from the
loss of self-renewal capacity of the mammary stem cell. As
discussed above, however, steroid receptor-expressing
epithelial cells are essential for ductal and lobular growth and
development. The absence of one or other of these essential
paracrine-mediating epithelial cell types could therefore explain
the absence of continued epithelial growth. The appearance of
growth senescence, then, could result without loss of the stem
cell proper, and could instead result from an alteration in the
microenvironment supporting stem cell function. No specific
experimental approach to the resolution of this issue has been
addressed in the mammary scientific literature.
CD49f, CD24, CD29, and so forth: meaning
and/or markers for stem cell activities
There seem to be conflicting views regarding the importance
of these surface markers and their relevance to the
prospective isolation of populations of epithelial cells
enriched for their ability to produce competent mammary
epithelial reconstitution in transplanted mammary fat pads.
Two groups have claimed that CD49fhi/CD24pos  or
CD29hi/CD24pos cells constitute populations highly enriched
for mammary stem cell activities competent for regeneration
Breast Cancer Research    Vol 10 No 1 Smith and Medina
Page 4 of 6
(page number not for citation purposes)of a complete and functional mammary gland and capable of
self-renewal [18,30]. Reports from another group indicate
that the bulk of in vivo reconstituting activity resides in the
CD24lo population and practically none is associated with
CD24hi in cells isolated from mammary tissue using this
single cell surface marker [31]. The CD24hi group was further
segregated into two separate fractions by sorting with
promininhi (CD133) and by the presence or absence of ERα
in CD24hi cells. These fractions also lacked in vivo
regenerating activities [32].
In another study, it was shown that PI-MEC (that is, lobule-
limited stem/progenitor cells) from WAP-Cre/chicken actin
gene promoter–GFP mammary glands were virtually all found
within the CD49fhi sorted population [17]. These studies
provide clear evidence that CD49fhi/CD24pos cell fractions
are not homogeneous for primary mammary stem cells;
nevertheless, the current literature continues to exhort the
high expression/content of these cell surface markers as
indicative of the presence of the mammary stem cell, when in
fact these markers are also highly expressed upon lineage-
limited lobular stem/progenitors.
What have we learned recently about mammary
stem cell biology from transplantation studies
and where shall we go from here?
To highlight the influence of diverse mammary epithelial cell
types in bringing about successful regeneration, near-limiting
dilutions of dispersed mammary epithelial cells were
comingled with testicular cells isolated from adult WAP-
Cre/Rosa26R mice. The resulting mixtures were inoculated
into cleared fat pads, and mammary ductal morphogenesis
was allowed to proceed for 6 to 8 weeks. Subsequently, a
fraction of the transplant hosts were maintained as virgins
and the rest were mated and permitted to complete a full
pregnancy, lactation and involution cycle. To determine
whether testicular cell progeny were present among the
involuted mammary epithelial cell population, X-gal whole-
mount staining was carried out. Only male cells possess the
WAP-Cre and Rosa26 LacZ reporter gene. LacZ-positive
cells among the regenerated mammary epithelium therefore
indicate the presence of testicular cell progeny. Of 22
successful mammary outgrowths, 18 outgrowths possessed
LacZ-positive mammary epithelium. The mammary nature of
these LacZ-positive cells was confirmed by staining for
mammary-specific markers for milk protein synthesis,
cytokeratins K5/K14 and smooth muscle actin. Fluorescent-
label in situ hybridization analysis confirmed that these cells
were male and indicated the absence of fusion between male
and female cells. LacZ-positive cells were found in all
second-generation transplants from the male/female chimeric
outgrowths, indicating their capacity for self-renewal.
These experiments demonstrate the overarching importance
of the signals provided by mammary epithelial cells for the
development of a microenvironment(s) capable of sustaining
stem cell activity and differentiation. Experiments have also
demonstrated that neural stem cells and lineage negative
bone marrow cells isolated from WAP-Cre/Rosa26 LacZ
reporter mice responded in the same manner as the testicular
cells in this mammary niche assay (unpublished observations).
In the human breast, little transplantation biology is available
due to technical difficulties in establishing mammary out-
growths in vivo. Progress has been made recently in this area
through humanization of the mouse mammary fat pad with
human-derived stromal cells [33]. The results of successful
implantations of normal human organoids indicate that
independent ductal, lobular and acinar structures may be
generated within humanized mouse mammary fat pads by
human mammary epithelial cells. This result and those demon-
strating the association of bi-potency with individual mammary
epithelial cells [34,35] suggest that a similar stem/progenitor
cell hierarchy exists in human breast epithelium.
The present discussion seeks to heighten the awareness of
those interested in studying the unresolved complexities
involved in mammary developmental biology and mammary
neoplastic progression, and further to suggest biological
events wherein our current level of ignorance could be
addressed through thoughtful investigation. Four critical
issues that require further study in mammary gland stem cell
biology and that are approachable through transplantation
study are as follows. First, what is the basis for growth
senescence in regenerating mammary epithelial populations?
This problem has only been examined for fragment
transplantation and little is known regarding this issue via
dilution studies of mammary cells isolated and dispersed from
serially transplanted populations. Second, how is growth
senescence avoided in premalignant populations? Alterations
in the expression of some genes (for example, p53 and
p19ARF [20,36,37]) result in escape from growth
senescence in mammary transplantation studies. What role
do these genes play in mammary stem cells or their
immediate progeny (niche)? Third, what are the relative roles
of the lineage-limited stem/progenitor populations in these
two foregoing issues? Finally, are the lineage-limited stem/
progenitor cells themselves bonafide targets for oncogenic
transformation?
From the foregoing it must be clear that none of the markers
used for concentrating mammary stem cell activities, as
determined by successful mammary outgrowths in vivo
(CD49fpos, CD29pos, CD24pos), produces a uniform popula-
tion of mammary stem cells. Rather, a mixture of stem cells,
lineage-limited stem/progenitors and differentiated epithelial
cells are essential for completion of a functional mammary
stem cell niche and are likely to be represented among this
population. Our challenge is not to sort out from this mixture
the primal mammary stem cell, but instead to comprehend the
interaction among these components that allows the long-
term maintenance of mammary stem cell activity. We wish to
Available online http://breast-cancer-research.com/content/10/1/203
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primordial mammary stem cell deflects our attention from the
important issue of extending our understanding of how
stem/progenitor cells and their progeny interact to maintain
mammary homeostasis and how this may be disturbed during
neoplastic transformation.
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